- Marinomed effectively tests new combination drug against VRTI
- Japan's Otsuka Pharma to acquire Visterra for $430 mn
- AbbVie Announces HUMIRA Patent License with Mylan
- Aenco Joins Enterprise Ethereum Alliance to boost healthtech industry
- Axol Bioscience introduces Human iPSC-derived Atrial Cardiomyocytes
- NICO Corp gets Patent for additional protection of its BrainPath technology
- Takeda & Celgene invest in Presage
- Minerva Neurosciences elects Jeryl Hilleman to Board of Directors
- Israel Govt to grant funds to GE, Change & Medtronic
- Qatar Health Ministry recalls 7 pharma products
- Ieon-nanodrugs announces collaboration with Takeda
- Polares Medical announces closing of $25M financing
- FDA approves Calcitriol’s new contract manufacturing submission
- Cerecor expands leadership team
-
Pharma | 05 January 2018 | News
AstraZeneca collaborates with Myriad Genetics for cancer therapy
AstraZeneca is working in collaboration with the molecular diagnostics firm Myriad Genetics’ for its tes...Read more
Digital Health | 05 January 2018 | News
Microsoft partners with Adaptive Biotechnologies
The tech giant Microsoft is partnering with Seattle biotech company Adaptive Biotechnologies on a year-long pr...Read more
-
Japan | 18 July 2018 | News
Japan's Otsuka Pharma to acquire Visterra for $430 mn
Japan's Otsuka Pharmaceutical recently announced that it has acquired US-based Visterra for approx...Read more
-
BioTech | 18 July 2018 | News
Marinomed effectively tests new combination drug against VRTI
Carragelose®, a broadly effective compound for treating cold viruses, can be combined with Xylometazoline,...Read more
-
World | 18 July 2018 | News
NICO Corp gets Patent for additional protection of its BrainPath technology
NICO Corporation, Neurosurgical medical device maker issued patent for additional protection around its unique...Read more
-
Pharma | 04 January 2018 | News
Europe's biggest private biotech company raises $270 million
Europe’s largest privately held biotech company, Germany-based BioNTech, has raised $270 million to supp...Read more
ASEAN – Emerging hotspot for Big pharmas
ASEAN is growing, and growing with it is the region’s pharma sector. With growth in developed markets flattening, pharma industry is betting on lucrative ASEAN markets for profits. Think of Asia’s emerging markets and the instant names that appear are India and China. Undoubtedly, these are huge markets for the industry. But apart from these main markets, ASEAN’s emerging markets, with an annual growth rate of 11 per cent and huge untapped potential, provide a massive opportunity for big pharma to expand and grow in this region.
